{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:53:19Z","timestamp":1790142799141,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"BMS-Pizfer Alliance unrestricted grant to Cancer & Thrombosis Section of the Spanish Society of Medical Oncology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03890-5","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T14:13:39Z","timestamp":1745676819000},"page":"4031-4039","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["External validation of a prediction model for bleeding events in anticoagulated cancer patients with venous thromboembolism (PredictAI)"],"prefix":"10.1007","volume":"27","author":[{"given":"Mar\u00eda Carmen","family":"Vi\u00f1uela-Ben\u00e9itez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Iglesias P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ortega Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garc\u00eda Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cacho Lav\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rut","family":"Porta i Balany\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garc\u00eda Adri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Carmona Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretel","family":"Ben\u00edtez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Santiago Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Lobo de Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"P\u00e9rez Altozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gallardo D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tejerina Peces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ochoa Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Ortiz Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria Eugenia","family":"Castell\u00f3n Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"D\u00edez Pedroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rosales Sueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"S\u00e1nchez-C\u00e1novas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mu\u00f1oz-Langa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"P\u00e9rez Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mart\u00ednez","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carmona-Bayonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Jim\u00e9nez-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-8249","authenticated-orcid":false,"given":"Andr\u00e9s Jes\u00fas","family":"Mu\u00f1oz Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"3","key":"3890_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02374.x.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"3890_CR2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","volume":"125","author":"AA Khorana","year":"2010","unstructured":"Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490\u20133. https:\/\/doi.org\/10.1016\/j.thromres.2009.12.023.","journal-title":"Thromb Res"},{"issue":"15","key":"3890_CR3","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/archinte.164.15.1653","volume":"164","author":"LS Elting","year":"2004","unstructured":"Elting LS, Escalante CP, Cooksley C, Avritscher EB, Kurtin D, Hamblin L, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164(15):1653\u201361. https:\/\/doi.org\/10.1001\/archinte.164.15.1653. (Erratum in: Arch Intern Med. 2008 Jun 9;168(11):1218).","journal-title":"Arch Intern Med"},{"issue":"10","key":"3890_CR4","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484\u20138. https:\/\/doi.org\/10.1182\/blood-2002-01-0108.","journal-title":"Blood"},{"issue":"2","key":"3890_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11912-019-0767-5","volume":"21","author":"HK Patel","year":"2019","unstructured":"Patel HK, Khorana AA. Anticoagulation in cancer patients: a summary of pitfalls to avoid. Curr Oncol Rep. 2019;21(2):18. https:\/\/doi.org\/10.1007\/s11912-019-0767-5.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"3890_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","volume":"33","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, American Society of Clinical Oncology, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654\u20136. https:\/\/doi.org\/10.1200\/JCO.2014.59.7351.","journal-title":"J Clin Oncol"},{"key":"3890_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.thromres.2020.12.031","volume":"199","author":"MA de Winter","year":"2021","unstructured":"de Winter MA, van Es N, B\u00fcller HR, Visseren FLJ, Nijkeuter M. Prediction models for recurrence and bleeding in patients with venous thromboembolism: a systematic review and critical appraisal. Thromb Res. 2021;199:85\u201396. https:\/\/doi.org\/10.1016\/j.thromres.2020.12.031.","journal-title":"Thromb Res"},{"issue":"5","key":"3890_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1055\/s-0041-1735251","volume":"122","author":"MA de Winter","year":"2022","unstructured":"de Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer-Westendorf J, Coppens M, et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost. 2022;122(5):818\u201329. https:\/\/doi.org\/10.1055\/s-0041-1735251.","journal-title":"Thromb Haemost"},{"issue":"4","key":"3890_CR9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1055\/a-2145-7238","volume":"124","author":"AT Cohen","year":"2024","unstructured":"Cohen AT, Wallenhorst C, Choudhuri S, Nassar A, Pollock KG, Martinez C. A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer. Thromb Haemost. 2024;124(4):324\u201336. https:\/\/doi.org\/10.1055\/a-2145-7238.","journal-title":"Thromb Haemost"},{"key":"3890_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03586-2","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2024","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Lecumberri R, Souto JC, Obispo B, Sanchez A, Aparicio J, et al. Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing. Clin Transl Oncol. 2024. https:\/\/doi.org\/10.1007\/s12094-024-03586-2. (Epub ahead of print. Erratum in: Clin Transl Oncol. 2024 Nov 19).","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"3890_CR11","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s12094-019-02265-x","volume":"22","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2020","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Jim\u00e9nez-Fonseca P, Carmona-Bayonas A, Mart\u00ednez de Castro E, Mu\u00f1oz Langa J, P\u00e9rez Segura P, et al. Cancer and thrombosis section, Spanish society of medical oncology (SEOM). TESEO, cancer-associated thrombosis registry from the Spanish society of medical oncology (SEOM). Clin Transl Oncol. 2020;22(8):1423\u20134. https:\/\/doi.org\/10.1007\/s12094-019-02265-x.","journal-title":"Clin Transl Oncol"},{"key":"3890_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejim.2020.05.031","volume":"78","author":"A Carmona-Bayonas","year":"2020","unstructured":"Carmona-Bayonas A, G\u00f3mez D, Mart\u00ednez de Castro E, P\u00e9rez Segura P, Mu\u00f1oz Langa J, Jimenez-Fonseca P, et al. A snapshot of cancer-associated thromboembolic disease in 2018\u20132019: first data from the TESEO prospective registry. Eur J Intern Med. 2020;78:41\u20139. https:\/\/doi.org\/10.1016\/j.ejim.2020.05.031.","journal-title":"Eur J Intern Med"},{"issue":"4","key":"3890_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12094-020-02472-x","volume":"23","author":"J Mu\u00f1oz-Langa","year":"2021","unstructured":"Mu\u00f1oz-Langa J, Jimenez-Fonseca P, Carmona-Bayonas A, de Castro EM, P\u00e9rez-Segura P, C\u00e1novas MS, et al. Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish society of medical oncology). Clin Transl Oncol. 2021;23(4):799\u2013811. https:\/\/doi.org\/10.1007\/s12094-020-02472-x. (Epub 2020 Aug 13).","journal-title":"Clin Transl Oncol"},{"key":"3890_CR14","volume-title":"Signal detection theory and psychophysics","author":"DM Green","year":"1966","unstructured":"Green DM, Swets JA. Signal detection theory and psychophysics. New York: Wiley; 1966."},{"issue":"1","key":"3890_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","volume":"143","author":"JA Hanley","year":"1982","unstructured":"Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29\u201336. https:\/\/doi.org\/10.1148\/radiology.143.1.7063747.","journal-title":"Radiology"},{"issue":"3","key":"3890_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1148\/radiology.148.3.6878708","volume":"148","author":"JA Hanley","year":"1983","unstructured":"Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839\u201343. https:\/\/doi.org\/10.1148\/radiology.148.3.6878708.","journal-title":"Radiology"},{"key":"3890_CR17","volume-title":"IBM SPSS statistics for windows, version 26.0","author":"IBM Corp. Released","year":"2019","unstructured":"IBM Corp. Released. IBM SPSS statistics for windows, version 26.0. Armonk: IBM Corp; 2019."},{"issue":"1","key":"3890_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","volume":"162","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55\u201363. https:\/\/doi.org\/10.7326\/M14-0697. (Erratum. in: Ann Intern Med. 2015 Apr 21;162(8):600.doi:10.7326\/L15-0078-4. PMID: 25560714).","journal-title":"Ann Intern Med"},{"issue":"5","key":"3890_CR19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010;138(5):1093\u2013100. https:\/\/doi.org\/10.1378\/chest.10-0134.","journal-title":"Chest"},{"issue":"1","key":"3890_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1160\/TH08-03-0193","volume":"100","author":"N Ru\u00edz-Gim\u00e9nez","year":"2008","unstructured":"Ru\u00edz-Gim\u00e9nez N, Su\u00e1rez C, Gonz\u00e1lez R, Nieto JA, Todol\u00ed JA, Samperiz AL, RIETE Investigators, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE registry. Thromb Haemost. 2008;100(1):26\u201331. https:\/\/doi.org\/10.1160\/TH08-03-0193.","journal-title":"Thromb Haemost"},{"issue":"4","key":"3890_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1160\/TH16-11-0830","volume":"117","author":"M Di Nisio","year":"2017","unstructured":"Di Nisio M, Raskob G, B\u00fcller HR, Grosso MA, Zhang G, Winters SM, et al. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017;117(4):784\u201393. https:\/\/doi.org\/10.1160\/TH16-11-0830. (Epub 2017 Feb 2).","journal-title":"Thromb Haemost"},{"issue":"2","key":"3890_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1160\/TH15-06-0474","volume":"115","author":"M Di Nisio","year":"2016","unstructured":"Di Nisio M, Ageno W, Rutjes AW, Pap AF, B\u00fcller HR. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thromb Haemost. 2016;115(2):424\u201332. https:\/\/doi.org\/10.1160\/TH15-06-0474. (Epub 2015 Oct 29).","journal-title":"Thromb Haemost"},{"issue":"2 Suppl","key":"3890_CR23","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e44S-e88S. https:\/\/doi.org\/10.1378\/chest.11-2292.","journal-title":"Chest"},{"key":"3890_CR24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02336-2020","author":"L Jara-Palomares","year":"2020","unstructured":"Jara-Palomares L, Jim\u00e9nez D, Bikdeli B, Muriel A, Rali P, Yamashita Y, RIETE investigators, et al. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.02336-2020.","journal-title":"Eur Respir J"},{"issue":"5","key":"3890_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3892\/etm.2021.10779","volume":"22","author":"MC Badescu","year":"2021","unstructured":"Badescu MC, Ciocoiu M, Badulescu OV, Vladeanu MC, Bojan IB, Vlad CE, et al. Prediction of bleeding events using the VTE-BLEED risk score in patients with venous thromboembolism receiving anticoagulant therapy (review). Exp Ther Med. 2021;22(5):1344. https:\/\/doi.org\/10.3892\/etm.2021.10779. (Epub 2021 Sep 22).","journal-title":"Exp Ther Med"},{"issue":"5","key":"3890_CR26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","volume":"48","author":"FA Klok","year":"2016","unstructured":"Klok FA, H\u00f6sel V, Clemens A, Yollo WD, Tilke C, Schulman S, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016;48(5):1369\u201376. https:\/\/doi.org\/10.1183\/13993003.00280-2016. (Epub 2016 Jul 28).","journal-title":"Eur Respir J"},{"issue":"4","key":"3890_CR27","doi-asserted-by":"publisher","first-page":"1800077","DOI":"10.1183\/13993003.00077-2018","volume":"51","author":"FA Klok","year":"2018","unstructured":"Klok FA, Barco S, Konstantinides SV. Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in stable anticoagulated patients with venous thromboembolism. Eur Respir J. 2018;51(4):1800077. https:\/\/doi.org\/10.1183\/13993003.00077-2018.","journal-title":"Eur Respir J"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03890-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03890-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03890-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:48:46Z","timestamp":1758721726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03890-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3890"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03890-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Personal financial interests: ACB reports receiving lecture grants from Esteve, Lilly, and Astellas; travel support from Amgen; and research funding from HRA Pharma-Esteve. AJMM\u2014consulting or advisory role: Regeneron, Sanofi, Bristol-Myers Squibb\/Pfizer, Leo Pharma, Daiichi Sankyo, Incyte, AstraZeneca, MSD Oncology, Lilly, Celgene, Novocure, Roche, Servier; Speakers\u2019 Bureau: Rovi, STADA, Menarini, Bayer; research funding: Celgene, Sanofi, Leo Pharma and Rovi; patents: risk assessment model in venous thromboembolism in cancer patients; travel, accommodation and expenses: AstraZeneca, Amgen, Merck Serono, Roche, Celgene, Pfizer. DCL\u2014consultant or advisory role: AstraZeneca, BMS; speaking: AstraZeneca, BMS, Leo Pharma, Rovi. EGD\u2014consultant or advisory role: Sanofi, Janssen, Astellas, Bayer, Ipsen, Pfizer, Roche, Novartis, Eisai, Recordati, BMS, MSD, AstraZeneca, Merck, Rovi, Daiichi Sankyo, Techdow, Lilly, GSK, advanced accelerator applications; speaking: Astellas, Janssen, Sanofi, Bayer, Ipsen, Pfizer, Roche, BMS, Rovi, Daiichi Sankyo, Leo Pharma, Eisai, Boehringer Ingelheim, Merck, EUSA Pharma\/Recordati, Lilly, advanced accelerator applications, GSK; grant support: Astellas, Janssen, Sanofi, Bayer, Ipsen, Ferrer, Pfizer, Roche, GSK, BMS, MSD, Merck, Recordati, AstraZeneca, Advanced accelerator applications;\u00a0travel\/accommodation expenses: Astellas, Janssen, Sanofi, BMS, Bayer, Ipsen, Roche, Novartis, Pfizer, Eisai, AstraZeneca, Leo Pharma. GBL\u2014speaking: MSD, SUNpharma, Pfizer, Pierre Fabre, Bristol Mayer, Roche, Merck, AstraZeneca. IGE\u2014consultant: AstraZeneca, Amgen, Merck, Leo Pharma, Rovi. JML\u2014speaking: GSK, MSD, AstraZeneca; travel, accommodations: Servier, MSD. LOM\u2014speaking: Leo Pharma and Rovi. MLM\u2014honoraria: Servier, Leo Pharma; travel, accommodations and expenses: AstraZeneca, Novartis, Ipsen, Servier, Pharma Mar, Roche. MAR\u2014MR\u2019s department has received a grant from SEOM (Spanish Society of Medical Oncology) for the assessment and completion of statistical analysis. MSC\u2014consultant or advisory role: KyowaKirin; research funding: Leo Pharma; speaking: Leo Pharma. Sanofi. Lundbeck; other: financial support for attending symposia (Sanofi, MSD, Esteve, Amgen, Servier, Angelini, Leo Pharma), financial support for educational programs (Angelini, Sanofi, Rovi, Leo Pharma, Servier, Merck), remunerations for authorship in clinical cases journals\/book chapters\/complete books (KyowaKirin, Mylan, Leo Pharma). PJF\u2014honoraria for speakers\u2019 bureau participation, and serving on advisory boards from Astellas, AstraZeneca, Bristol-Myers Squibb (BMS), Esteve, Merck Sharp & Dohme (MSD), Novartis, Nutricia, Pfizer, Rovi, Takeda, and Viatri and research grants from Astellas, AstraZeneca, BMS, and MSD. PPS\u2014consultant or advisory role: Roche, BMS, MSD, AstraZeneca, Merck, Rovi, Novocure, LeoPharma; speaking: Roche, BMS, MSD, AstraZeneca, Merck, Rovi, Novocure, LeoPharma; grant support: Roche, BMS, MSD, AstraZeneca, Merck, Rovi, Novocure, LeoPharma; travel\/accommodation expenses: Roche, BMS, MSD, AstraZeneca, Merck, Rovi, Novocure, LeoPharma. CIP, CDP, DB, EMC, IGE, JPA, JASC, JTP, MCC, MCVB, MJOM, MRS, POR, RPB, SGA, VECR: the rest of authors declare no competing interests for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"All participants provided informed consent prior to their participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}